2,334 results on '"Cornely, Oliver A."'
Search Results
252. Impfausweis für die Hämatologie und Onkologie [Patienten]
253. en ECCM score til at måle kvalitet af klinisk håndtering af kronisk pulmonal aspergillose
254. EQUAL Trichosporon Skoru 2022
255. Skora EQUAL Trichosporon 2022
256. EQUAL CPA スコア 2022
257. Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies : 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)
258. Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
259. A Randomized, Placebo-controlled Trial of Preemptive Antifungal Therapy for the Prevention of Invasive Candidiasis Following Gastrointestinal Surgery for Intra-abdominal Infections
260. 15 Antifungal Pharmacokinetics
261. 14 Therapeutic Strategies in Fungal Infections
262. Clinical-scale isolation of the total Aspergillus fumigatus–reactive T–helper cell repertoire for adoptive transfer
263. Candida auris in Germany and Previous Exposure to Foreign Healthcare
264. Adressen
265. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project
266. Fungal infections in haemato-oncology
267. Pneumonie unter Immunsuppression: Antimikrobielle Substanzen
268. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
269. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
270. SARS-CoV-2 vaccination in CLL: how often is enough?
271. Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany
272. 231. Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis
273. 754. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32)
274. 221. Assessment and Proposed Revision of Clinical Trial Clostridioides difficile Infection Clinical Response and Outcomes Definitions
275. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit (Preprint)
276. EQUAL CPA Score 2022: a tool to measure guideline adherence for chronic pulmonary aspergillosis
277. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
278. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2
279. Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
280. Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review
281. Reason and reality—identifying barriers to patient enrolment for clinical trials in invasive candidiasis
282. B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
283. Plain language summary: use of isavuconazole in Chinese patients with an invasive fungal disease
284. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination
285. Monkeypox diagnostic and treatment capacity at epidemic onset: A VACCELERATE online survey
286. Intensive care medicine research agenda on invasive fungal infection in critically ill patients
287. Abridged version of the AWMF guideline for the medical clinical diagnostics of indoor mould exposure: S2K Guideline of the German Society of Hygiene, Environmental Medicine and Preventive Medicine (GHUP) in collaboration with the German Association of Allergists (AeDA), the German Society of Dermatology (DDG), the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Occupational and Environmental Medicine (DGAUM), the German Society for Hospital Hygiene (DGKH), the German Society for Pneumology and Respiratory Medicine (DGP), the German Mycological Society (DMykG), the Society for Pediatric Allergology and Environmental Medicine (GPA), the German Federal Association of Pediatric Pneumology (BAPP), and the Austrian Society for Medical Mycology (ÖGMM)
288. The “Choosing Wisely” initiative in infectious diseases
289. Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)
290. EDITORIAL COMMENTARY: Galactomannan Testing During Mold-Active Prophylaxis
291. COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
292. Infektiologie
293. Onkologie
294. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope
295. Monkeypox in children and adult women in Europe: Results from a flash VACCELERATE pilot survey
296. STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE network
297. Invasive Trichoderma spp. infections: clinical presentation and outcome of cases from the literature and the FungiScope® registry
298. A pilot surveillance report of SARS-CoV-2 rapid antigen test results among volunteers in Germany, 1st week of July 2022
299. COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey
300. Transparently report on the process of moving from evidence to recommendation – Authors' reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.